Licarin A

Licarin A ((+) -Licarin A), a neolignan, significantly and dose-dependently reduces TNF-α production (IC50=12.6 μM) in dinitrophenyl-human serum albumin (DNP-HSA) -stimulated RBL-2H3 cells. Anti-allergic effects. Licarin A reduces TNF-α and PGD2 production, and COX-2 expression[1].

Product Specifications

CAS Number

[51020-86-1]

Product Name Alternative

(+) -Licarin A

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

COX; Prostaglandin Receptor; TNF Receptor

Type

Natural Products

Related Pathways

Apoptosis; GPCR/G Protein; Immunology/Inflammation

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/licarin-a-1.html

Purity

99.83

Solubility

DMSO : ≥ 50 mg/mL|H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

OC1=CC=C([C@@H]2OC3=C(OC)C=C(/C=C/C)C=C3[C@H]2C)C=C1OC

Molecular Formula

C20H22O4

Molecular Weight

326.39

Precautions

H302, H315, H319, H335

References & Citations

[1]Takuya Matsui, et al. Licarin A Is a Candidate Compound for the Treatment of Immediate Hypersensitivity via Inhibition of Rat Mast Cell Line RBL-2H3 Cells. J Pharm Pharmacol. 2015 Dec;67 (12) :1723-32.